#Japan #Immunotherapy #Tokyo #Blood Cancer #Tokyo Medical Institute

Upcoming Lecture on Blood Cancer Treatment

The Tokyo Metropolitan Institute of Medical Research is excited to announce the inaugural public lecture for 2026, scheduled for May 23rd. This lecture will delve into the latest advancements in blood cancer treatment, specifically focusing on immunotherapy's role in combating this disease. Experts from various fields will share their insights to enhance public understanding of these significant medical developments.

Event Details

• - Date: Saturday, May 23, 2026
• - Time: 14:00 – 15:30
• - Format: Hybrid event – In-person and online via Zoom

The featured topic for this lecture is “New Blood Cancer Treatments: The Era of Immunotherapy.” Two prominent speakers will lead the presentation: Takuya Miyazaki, a lecturer from the Hematology Department of Yokohama City University Hospital, and Teruhiko Suzuki, the leader of the Immunological Drug Research Group at the Tokyo Metropolitan Institute.

Current Trends in Blood Cancer Treatment

In recent years, traditional chemotherapy techniques have evolved significantly, complemented by cutting-edge immunotherapy strategies. One of the most promising advancements is bispecific antibodies, designed to direct immune cells towards cancer cells, effectively triggering an attack. Additionally, CAR-T therapy, which utilizes patients' modified immune cells, has demonstrated remarkable effectiveness.

Moreover, techniques like hematopoietic stem cell transplantation have broadened treatment options by leveraging the immune response from transplanted donor cells. This paradigm shift in blood cancer treatment emphasizes the power of the immune system, which is becoming a cornerstone of modern oncology.

During this lecture, attendees will gain valuable insights into the ongoing research and breakthroughs in blood cancer treatment. Experts will present the latest findings, highlighting how immunotherapy is revolutionizing patient care and outcomes.

Registration Information

The lecture anticipates an audience of 600 participants, with 100 seats available for in-person attendance at the Tokyo Metropolitan Institute and 500 slots for online viewing. Those interested can register in advance, as seats are limited and allocated on a first-come, first-served basis.

To register for in-person attendance:
You can use the application form available on the Tokyo Medical Institute website or send a postcard specifying your interest in attending the lecture. Please include your name, age, contact number, and the names and ages of any accompanying guests.

Application details:

• - Form link: Tokyo Medical Institute Application
• - Postal address:

Tokyo Metropolitan Institute of Medical Research
Public Relations Department
2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506

To register for online attendance:
Follow the same procedure through the provided application form on the institute’s website.

Deadline for registration:

• - In-person attendance: May 21, 2026
• - Online attendance: Until the start of the lecture

Participants who complete the survey during the lecture will receive 100 Tokyo Points. For additional details, please refer to the official Tokyo app website: Tokyo App.

Don’t miss this opportunity to learn about the transformative impacts of immunotherapy on blood cancer treatments and engage with leading researchers in the field.